Prospect News: News for Bristol-Myers Squibb Co.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with B > Issuers starting with B, CV only > All stories on Bristol-Myers Squibb Co. > Stories on Bristol-Myers Squibb Co., CV only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Bristol-Myers Squibb Co.

10/5/2020	BKCVIG	S&P shifts Bristol-Myers view to negative
5/2/2019	BKCVIG	S&P rates Bristol-Myers notes A+
4/17/2019	BKCVIG	S&P rates Bristol-Myers notes A+
1/7/2019	CVIG	Fitch puts Bristol-Myers on watch
1/3/2019	CVIG	Moody's may lower Bristol-Myers
6/5/2018	BKCVIG	Fitch affirms Bristol-Myers
2/7/2018	BKCVIG	Moody’s changes Bristol-Myers to stable
2/22/2017	CVIG	Fitch: Bristol-Myers notes A-
2/22/2017	CVIG	Moody’s gives Bristol-Myers notes A2
2/22/2017	CVIG	S&P: Bristol-Myers notes A+
2/13/2017	CVIG	Moody’s: Bristol-Myers view to negative
4/30/2015	CVIG	Fitch: Bristol-Myers bond A-
4/29/2015	CVIG	S&P: Bistol-Meyers notes A+
4/29/2015	CVIG	Moody’s rates Bristol-Myers notes A2
12/11/2014	CVIG	Fitch lifts Bristol-Myers view to stable
12/23/2013	CVIG	Fitch: Bristol-Myers view negative
10/24/2013	CVIG	S&P: Bristol-Myers notes A+
10/24/2013	CVIG	Moody's gives Bristol-Myers notes A2
9/23/2013	CVIG	Moody's: Bristol-Myers view negative
7/1/2013	CVIG	Fitch cuts Bristol-Myers to A-
5/16/2013	CV	Bristol-Myers Squibb announces intention to delist its preferred stock
8/13/2012	CVLM	Amylin announces change-of-control put option for 3% convertibles
7/26/2012	CVIG	Moody's rates Bristol-Myers Squibb notes A2
7/26/2012	CVIGPF	Bristol-Myers Squibb files automatic shelf for stock, preferreds, debt
7/26/2012	CVIGPF	S&P: Bristol-Myers Squibb notes A+, preferreds A-
7/3/2012	BKCVIG	Fitch cuts Bristol Myers Squibb
7/2/2012	CVIG	Moody's affirms Bristol-Myers
5/31/2012	BKCVIG	S&P lifts health companies
1/11/2012	CVIG	Fitch: Bristol-Myers unchanged
1/9/2012	CVIG	Moody's: Bristol-Myers unaffected by acquisition
1/9/2012	CVIG	S&P: Bristol-Myers unaffected
11/22/2011	CVIG	Moody's: Bristol-Myers loan A2
7/25/2011	CVIG	Fitch affirms Bristol-Myers
8/27/2010	CVIG	Fitch: Bristol-Myers Squibb outlook negative
11/16/2009	CVIG	Fitch: Bristol-Myers unchanged
11/16/2009	CVIG	Moody's: Bristol-Myers unchanged
10/26/2009	CV	Medarex tender offer for 2.25% convertibles expires; no notes tendered
9/24/2009	CV	Medarex holders may put 2.25% convertibles following change of control
9/12/2008	CVIG	Fitch affirms Bristol-Myers Squibb
8/27/2008	CV	Market Commentary: Amylin, Cell Genesys fall on product bombshells; Bristol-Myers stands pat; Fannie Mae extends gains
7/31/2008	CVIG	Moody's: Bristol-Myers view negative
4/28/2008	CVIG	S&P assigns Bristol-Myers notes A+
4/28/2008	CVIG	Moody's gives Bristol-Myers notes A2
4/28/2008	CVIG	Fitch rates Bristol-Myers notes A+
4/28/2008	CVIG	Bristol-Myers Squibb files automatic shelf registration
8/3/2007	CV	Fitch affirms Bristol-Myers
6/22/2007	CV	S&P ups Bristol-Myers outlook to stable
6/19/2007	CV	Market Commentary: VeriFone improves on debut; Companhia Vale do Rio Doce gains in gray; Bristol-Myers rises on legal win
2/12/2007	CV	Market Commentary: Bristol-Myers slips on dashed merger hopes; Anixter prices at rich end; Illumina seen as fair; Essex in play
1/30/2007	CV	Market Commentary: Bristol-Myers gains further on takeover rumors; Sunpower quiet amid borrow concerns; Kyphon plans deal
1/29/2007	CV	Market Commentary: Bristol-Myers gains amid takeover talk; Sunpower distribution could be tight; Amgen continues decline
11/17/2006	CV	Moody's rates Bristol-Myers Squibb notes A2
11/17/2006	CV	Fitch rates Bristol-Myers Squibb notes A+
11/16/2006	BTCVHY	S&P assigns Bristol-Myers notes A+
9/12/2006	BTCV	Moody's cuts Bristol-Myers Squibb
9/6/2006	BTCV	S&P affirms Bristol-Myers Squibb
8/10/2006	CV	New Issue: Lehman prices $10 million 9.55% Yeelds linked to Bristol-Myers Squibb
8/9/2006	BTCV	Moody's may downgrade Bristol-Myers Squibb
8/9/2006	CV	Lehman plans issue of 9.55% Yeelds linked to Bristol-Myers Squibb
8/8/2006	BTCV	Fitch puts Bristol-Myers Squibb on negative watch
8/8/2006	BTCV	S&P: Bristol-Myers Squibb on watch
7/17/2006	CV	New Issue: ABN Amro prices $1.45 million 8.75% exchangeables linked to Bristol-Myers Squibb
7/12/2006	CV	ABN Amro plans issue of 8.75% Knock-in Reverse Exchangeables linked to Bristol-Myers Squibb
2/15/2006	BTCV	Moody's affirms Bristol-Myers Squibb
1/17/2006	BTCV	New Issue: Barclays sells $2.5 million 8% exchangeables linked to Bristol-Myers Squibb
1/10/2006	CV	Barclays plans issue of 8% exchangeables linked to Bristol-Myers Squibb
9/16/2005	CV	Fitch affirms Bristol-Myers Squibb
7/14/2005	CV	Market Commentary: GM, Ford convertibles move up in active trade; AMD, Genzyme, airlines also gain, other sectors quiet
1/14/2005	CV	Market Commentary: CNet gains 4 points; Collegiate Pacific higher; UnumProvident up; Wyeth rises, Schering drops
1/12/2005	CV	S&P: Bristol-Myers Squibb unaffected
1/5/2005	CV	Market Commentary: Celanese, AtheroGenics talk emerges; Delta cuts fares but convertibles quiet; OMI firmer
12/15/2004	CV	New Issue: ABN Amro sells $12.5 million 11.75% reverse exchangeables linked to Bristol-Myers Squibb
11/2/2004	CV	New Issue: Lehman prices $7 million 1.6% up 13.75% notes linked to Bristol-Myers
9/29/2004	CV	Fitch rates Bristol-Myers Squibb A+
9/24/2004	CV	Market Commentary: Calpine new issue trade seen awkward; Dobson off on buy; PMA Capital exchange seen
9/14/2004	CV	Market Commentary: Allied Waste issues dumped; Interpublic mandatory eyed; Mercury rises ahead of Oracle
8/26/2004	CV	New Issue: ABN Amro sells $2.6 million 9% reverse exchangeables linked to Bristol-Myers
8/16/2004	CV	S&P cuts Bristol-Myers
5/20/2004	CV	Market Commentary: Airline paper cheapens further, despite rise in stocks; Guilford shelf uplifts holders of rich bonds
3/10/2004	CV	Market Commentary: Level 3 falls on Global Crossing meltdown; Marriott offered at par in gray market; biotechs plummet
2/13/2004	CV	S&P: Bristol-Myers unaffected
2/12/2004	CV	Market Commentary: Buyers propel new AMR convert; Bristol-Myers up on Erbitux news; Incyte trades at par in gray market
2/3/2004	CV	Market Commentary: First Data's call catches some off guard, Delta reoffered at 97, descends to 95.75 bid; Tyco up
11/24/2003	CV	Market Commentary: Market hunts for Thanksgiving deal, Ciber answers the call with small issue; trading flow low
10/8/2003	CV	Market Commentary: Kodak, Placer Dome track gray market levels out of the gate; Simon positions seen lightening
10/7/2003	CV	Market Commentary: Kodak bid up 2.25 points, Placer Dome up 2.5 in gray market action; Finisar, iDine emerge after close
10/6/2003	CV	New Issue: Lehman prices $23.6 million 1.6% notes linked to Bristol-Myers
9/30/2003	CV	Market Commentary: Williams bonds gain 2.25 points, mandatory up slightly but more sellers seen; LSI loses 4-5 points
9/26/2003	CV	Market Commentary: Market not ready to swallow Bristol-Myers Squibb; Cracker Barrel drops 1.5 on dividend
9/26/2003	CV	New Issue: Bristol-Myers prices $1 billion floater at Libor minus 50 bps, up 60%
9/25/2003	CV	S&P rates Bristol-Myers convertible AA-
9/25/2003	CV	Market Commentary: Pharma Resources gains to 104 despite complaint; Bristol-Myers jumbo seen offered at par in gray
9/24/2003	CV	Bristol-Myers $1 billion floater to yield Libor minus 50 to 75 bps, up 60-65%
9/24/2003	CV	Market Commentary: CKE bids beefed up to 107; Flextronics expected to lose "big points" on jury award
6/23/2003	CV	New Issue: ABN Amro sells $11.5 million 10% reverse exchangeables linked to Briston-Myers
6/3/2002	CV	New Issue: ABN Amro prices $16 million 11% reverse exchangeables linked to Bristol-Myers

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.